Chinese scientists highlight social impact of Cuban medicine
Havana, Aug 5 (RHC) Chinese scientists highlighted this Saturday the social impact on China of Nimotuzumab, a humanized monoclonal antibody from Cuba approved for the treatment of pancreatic cancer.
Dr. Qin Shukui thanked the Chinese-Cuban joint venture Biotech Pharma (BPL) on behalf of the Chinese Society of Clinical Oncology, for expanding the application of this drug in Beijing beyond therapy against nasopharyngeal cancer.
According to the researcher, the positive results of the Nimotuzumab clinical trial may benefit more patients with this type of cancer. He commented that despite the commonness of this condition, the results of the treatment at a global level are very poor, for this reason new advances are urgently needed and there is a great unmet clinical need.
Qin thanked the scientists from the 23 research centers involved in the clinical study of this humanized monoclonal antibody. Likewise, he praised the Cuban Academy of Sciences and the importance that the biomedical industry has on the island.
Nimotuzumab was the first product approved for commercialization by BPL and the first humanized monoclonal antibody in China since 2008. China's National Drug Administration -the industry's highest regulator- recently approved its use for the treatment of pancreatic cancer.
The Chinese entity referred to the good results of the injectable product in clinical studies, its effectiveness in inhibiting the growth of malignant cells, and its widespread use since 1998 in Cuba and other nations around the world.
In this regard, Mayda Mauri, first vice president of the BioCubaFarma company, said that apart from its success, BPL has made a very significant contribution to health care in both countries, especially during the Covid-19 pandemic.
She recalled that the company supplied Cuba with Nimotuzumab and thanks to this collaboration, the production facilities of the Molecular Immunology Center were able to dedicate themselves to developing the Sovereign vaccine.
